TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19340896
Drug: Tricyclic antidepressants
Normalized name: TRICYCLIC ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tricyclic antidepressants (TCAs) including amitriptyline, imipramine, desipramine, doxepin, and trimipramine
Study: 11300388
Drug: Epidural solution
Normalized name: Lidocaine Hydrochloride 1% Epidural Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural solution with fentanyl (SBAF)
Study: 11300388
Drug: Epidural solution
Normalized name: Lidocaine Hydrochloride 1% Epidural Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural solution without fentanyl (SBA)
Study: 11300388
Drug: Propofol anaesthesia
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol anaesthesia and epidural solution without fentanyl (PBA)
Study: 7890063
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of E2 and P
Study: 342295
Drug: Diflucortolone valerate
Normalized name: diflucortolone valerate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diflucortolone valerate 0.1% cream
Study: 342295
Drug: Diflucortolone valerate
Normalized name: diflucortolone valerate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diflucortolone valerate 0.1% ointment
Study: 342295
Drug: Diflucortolone valerate
Normalized name: diflucortolone valerate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diflucortolone valerate 0.1% fatty ointment
Study: 342295
Drug: Fluocinolone acetonide
Normalized name: Fluocinolone Acetonide
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluocinolone acetonide 0.025% ointment
Study: 31319510
Drug: Anserine/Carnosine Supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anserine/Carnosine Supplementation (750 mg of anserine and 250 mg of carnosine per day)
Study: 31319510
Drug: Anserine/Carnosine Supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anserine/Carnosine Supplementation (750 mg of anserine and 250 mg of carnosine per day) in APOE4 (+) subjects
Study: 28690011
Drug: Nintedanib maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nintedanib maintenance treatment
Study: 28690011
Drug: Placebo maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo maintenance treatment
Study: 23680226
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (TXA) - 1 g intravenously as a bolus immediately after randomization, followed by continuous infusion of 1 g per 8 hours until aneurysm treatment or maximum of 24 hours.
Study: 23680226
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment without TXA.
Study: 16925104
Drug: Early treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early treatment of mild anemia with erythropoietic therapy
Study: 16925104
Drug: Erythropoietic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoietic therapy
Study: 12958322
Drug: Aspirin plus
Normalized name: Aspirin Plus Antacid Extra Strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin plus dipyridamole 400 mg/d
Study: 12958322
Drug: Aspirin 30
Normalized name: aspirin 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 30 to 325 mg/d
Study: 7514030
Drug: Granulocyte colony-stimulating
Normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granulocyte colony-stimulating factor (G-CSF) (Filgrastim) at a dose of 5 micrograms/kg/day i.m. from day 6 to day 19
Study: 7514030
Drug: Mitoxantrone (DHAD)
DrugBank: Mitoxantrone (DB01204)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitoxantrone (DHAD) 12 mg m-2 i.v. on day 1; Ifosfamide (IFO) 4 g m-2 i.v. on days 1 and 2; Mesna 800 mg m-2 i.v. t.i.d. on days 1 and 2
Study: 29268948
Drug: Chemotherapy (vinflunine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (vinflunine 320 mg/m2, paclitaxel 175 mg/m2, or 75 mg/m2 docetaxel) every 3 weeks
Study: 20636964
Drug: Anaesthetic cream
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anaesthetic cream (EMLA) applied to the lower leg for 1.5 hours
Study: 20636964
Drug: Placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cream applied to the lower leg for 1.5 hours
Study: 15102391
Drug: Anaesthetic cream
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anaesthetic cream (EMLA)
Study: 17240783
Drug: Low Glycemic
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low Glycemic Index (LGI) meal, 2 g/kg body mass CHO, ingested 3 hours prior to exercise
Study: 17240783
Drug: High Glycemic
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High Glycemic Index (HGI) meal, 2 g/kg body mass CHO, ingested 3 hours prior to exercise
Study: 31944084
Drug: Endophytic rhizobacteria
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endophytic rhizobacteria treatment
Study: 30093516
Drug: Enhanced rehabilitation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced rehabilitation package (patient‐held information workbook, goal‐setting diary, and up to six additional therapy sessions)
Study: 16824240
Drug: S(+) ketamine
Normalized name: (S)-ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: S(+) ketamine (0.05 mg kg‐1, 1.0 mL)
Study: 16824240
Drug: Fentanyl (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (25 microg, 1.0 mL)
Study: 16824240
Drug: 0.9% saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% saline (1.0 mL)
Study: 12865483
Drug: Treatment of
Normalized name: DRUGS FOR TREATMENT OF LEPRA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of hypertension in subjects aged 80 years and older
Study: 6838744
Drug: 0.5% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% bupivacaine 2-3.5 ml
Study: 30786754
Drug: Empagliflozin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin (10 mg for the first 4 weeks, then force-titrated to 25 mg until week 24)
Study: 27129007
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of allopurinol (200 mg)
Study: 27129007
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation of allopurinol (200 mg)
Study: 22650250
Drug: Wireless capsule
Normalized name: careless weed pollen extract
DrugBank: Amaranthus palmeri pollen (DB10459)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wireless capsule pH‐metry (WC)
Study: 21048707
Drug: Oral microdose
Normalized name: LANCET,MICRODOT SAFETY 28G
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral microdose of (14)C-labeled acetaminophen (AAP)
Study: 9484756
Drug: Pentoxifylline (PTX)
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentoxifylline (PTX) at a dose of 800 mg/day, then 1200 mg/day
Study: 7648765
Drug: E3810 (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: E3810 (20 mg)
Study: 358021
Drug: Vincamine hydrochloride,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vincamine hydrochloride, administered intramuscularly for 10 days
Study: 358021
Drug: Dihydrogenated ergotoxine
Normalized name: Dihydrogen
DrugBank: Hydrogen (DB15127)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydrogenated ergotoxine derivative, administered intramuscularly for 10 days
Study: 15351795
Drug: Gliclazide (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gliclazide (20 mg/day)
Study: 15351795
Drug: Nateglinide (270
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nateglinide (270 mg/day, 90 mg t.i.d.)
Study: 11018853
Drug: Switch to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switch to ZDV + 3TC therapy (switch arm)
Study: 8339870
Drug: Verapamil 360
Normalized name: verapamil 360 mg/24 hours oral capsule, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil 360 mg daily for 4 weeks
Study: 3825912
Drug: 300 to
Normalized name: tenofovir disoproxil
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 300 to 400 mg 3‐OHQ orally
Study: 3825912
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg quinidine base intravenously
Study: 3825912
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 300 to 400 mg 3‐OHQ orally and 150 mg quinidine base intravenously
Study: 28549592
Drug: Collaborative pharmacist-physician
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collaborative pharmacist-physician medication therapy management (MTM) program
Study: 22425375
Drug: Radial extracorporeal
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radial extracorporeal shock wave therapy (rESWT) - 1500 pulses, 8 Hz, 3 bars, 4 sessions once a week
Study: 20388647
Drug: Eplerenone (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eplerenone (25 mg every other day to 50 mg daily, adjusted based on serum potassium)
Study: 16468962
Drug: TAC-SRL2 mg
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TAC-SRL2 mg
Study: 16468962
Drug: TAC-SRL0.5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAC-SRL0.5 mg
Study: 10961218
Drug: Conventional CT
Normalized name: CT-179
DrugBank: CT-179 (DB17114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional CT (sequential mode)
Study: 8928758
Drug: GH (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH (0.3 mg.kg‐1.day‐1 sc)
Study: 3882269
Drug: Tiapamil (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiapamil (1 mg/kg followed by 25 micrograms/kg/min over 36 hr)
Study: 29020467
Drug: Fractional picosecond
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fractional picosecond 1,064 nm laser plus 4% hydroquinone cream
Study: 29020467
Drug: 4% hydroquinone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% hydroquinone cream only
Study: 25900347
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g daily of placebo gel applied topically + periodontal debridement
Study: 25900347
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g daily of a 15% Mtz benzoate gel applied topically + periodontal debridement
Study: 25900347
Drug: 750 mg
Normalized name: bran 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg Mtz (Flagyl(®)) daily single dose + periodontal debridement
Study: 20127212
Drug: Subcutaneous indwelling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous indwelling vacuum drainage
Study: 18540740
Drug: Medication (withdrawn
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication (withdrawn onto pill-placebo)
Study: 18540740
Drug: Medication continuation
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication continuation
Study: 7594103
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose sematilide (0.75 then 0.3 mg/min)
Study: 7594103
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose sematilide (1.5 then 0.6 mg/min)
Study: 7594103
Drug: Neither low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neither low nor high dose sematilide
Study: 7594103
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose sematilide
Study: 27841822
Drug: Norepinephrine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norepinephrine (10 to 60 μg/min)
Study: 26231757
Drug: EAT intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EAT intervention delivered by dietitians during usual consultations, based on behaviour change counselling methods including motivational interviewing and cognitive-behavioural therapy.
Study: 26231757
Drug: Control condition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control condition providing treatment as usual before switching to EAT intervention.
Study: 21507143
Drug: Procalcitonin (PCT)
Normalized name: Procalcitonin
DrugBank: Procalcitonin (DB14812)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procalcitonin (PCT) guidance for antibiotic treatment
Study: 21507143
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (current guidelines for antibiotic treatment)
Study: 19476770
Drug: Oral discussion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral discussion and written pamphlet outlining the risks of the procedure
Study: 19476770
Drug: Traditional oral
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional oral dialogue of the surgical risks
Study: 30999554
Drug: AA mixture
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: AA mixture containing 3600 mg of arginine, 2200 mg of valine, and 200 mg of serine
Study: 28678853
Drug: Generic alendronate
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Generic alendronate (Bonmax®) 70 mg/week
Study: 28678853
Drug: Brand alendronate
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brand alendronate (Fosamax®) 70 mg/week
Study: 23535090
Drug: Combined antihistamines
Normalized name: Ahist Antihistamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined antihistamines and leukotriene antagonists
Study: 11835741
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen therapy (HBO), 3 courses of treatment
Study: 11835741
Drug: Dehydrating, cortical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dehydrating, cortical steroid and antibiotic therapy (Control)
Study: 7818588
Drug: Azelastine hydrochloride
Normalized name: Azelastine Hydrochloride
DrugBank: Azelastine (DB00972)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Azelastine hydrochloride 8.8 mg
Study: 7818588
Drug: Azelastine hydrochloride
Normalized name: Azelastine Hydrochloride
DrugBank: Azelastine (DB00972)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Azelastine hydrochloride 17.6 mg
Study: 30110579
Drug: Talazoparib (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Talazoparib (1 mg once daily)
Study: 30110579
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (capecitabine, eribulin, gemcitabine, or vinorelbine in continuous 21-day cycles)
Study: 25714598
Drug: Inclacumab (0.03-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inclacumab (0.03-20 mg/kg)
Study: 21349483
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate (154 mEq/L, 0.5 ml/kg bolus before contrast, followed by infusion at 1 ml/kg/hour for 6 hours)
Study: 21349483
Drug: Sodium chloride
Normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium chloride (0.5 ml/kg bolus before contrast, followed by infusion at 1 ml/kg/hour for 6 hours)
Study: 18753003
Drug: Rotigotine transdermal
Normalized name: Rotigotine Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rotigotine transdermal patch (0.5-4mg/24h)
Study: 9602596
Drug: Metoclopramide 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide 0.2 mg kg‐1
Study: 2667745
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no tamoxifen therapy)
Study: 31282592
Drug: Itraconazole (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole (200 mg on days 2-7) with Itacitinib (200 mg on days 1 and 6)
Study: 31282592
Drug: Rifampin (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampin (600 mg on days 2-9) with Itacitinib (200 mg on days 1 and 9)
Study: 21831711
Drug: Immediate pre-TURBT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate pre-TURBT EMDA mitomycin (40 mg in 100 mL sterile water with 20 mA pulsed electric current for 30 min)
Study: 19350369
Drug: Manualized behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manualized behavioral treatment including motivational interviewing and cognitive therapy
Study: 14977161
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg gum
Study: 14977161
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg gum
Study: 14977161
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg tablet
Study: 9244228
Drug: Midodrine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midodrine (5 to 10 mg)
Study: 9244228
Drug: I.V. saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: I.V. saline (1 L)
Study: 27165542
Drug: Acetylic Salicylic
Normalized name: acetyl salicylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetylic Salicylic Acid (ASA) 500 mg once daily for 12 weeks
Study: 24840857
Drug: Creatine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine supplementation (20 g day(‐1) for 7 days followed by 5 g day(‐1))
Study: 18608735
Drug: Pimecrolimus 1%
Normalized name: PIMECROLIMUS 1% CREAM,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pimecrolimus 1% cream plus NB-UVB
Study: 14572747
Drug: Bicalutamide 150
Normalized name: bicalutamide 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bicalutamide 150 mg in addition to standard care
Study: 10701823
Drug: Candesartan cilexetil
Normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Candesartan cilexetil (8 mg)
Study: 3628610
Drug: d-amphetamine 5
Normalized name: amphetamine / dextroamphetamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-amphetamine 5 mg/70 kg
Study: 3628610
Drug: d-amphetamine 10
Normalized name: amphetamine / dextroamphetamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-amphetamine 10 mg/70 kg
Study: 24139558
Drug: Placebo (isotonic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (isotonic saline 1.25 ml/kg/doses intravenously every 12 hours for 48 hours)
Study: 22337227
Drug: DHA-rich fish
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA-rich fish oil (1.1 g/d n-3 LCPUFA)
Study: 20410410
Drug: Low-dose ungated
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose ungated MDCT
Study: 15955616
Drug: 0.625 mg
Normalized name: estrone 0.625 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625 mg conjugated equine estrogen (CEE) + 2.5 mg medroxyprogesterone acetate (MPA)
Study: 15955616
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg estradiol valerate
Study: 12217947
Drug: Baclofen (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baclofen (15 mg/day for the first 3 days, then 30 mg/day for 27 days)
Study: 8607000
Drug: Chronic CPAP
Normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic CPAP therapy (Continuous Positive Airway Pressure)
Study: 7386493
Drug: Thyroid hormone
Normalized name: Thyroid hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyroid hormone
Study: 31704188
Drug: Oral calcitriol
Normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral calcitriol at 0.25 μg, 3 times weekly with ACEI or ARB
Study: 30945478
Drug: High Concentration
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High Concentration Oxygen Therapy (HCOT)
Study: 30945478
Drug: Titrated Oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Titrated Oxygen Therapy (TOT)
Study: 27020489
Drug: 200 μg sublingual
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 μg sublingual misoprostol with cervical laminaria
Study: 27020489
Drug: 400 μg sublingual
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 μg sublingual misoprostol without laminaria
Study: 23594463
Drug: Penicillin V
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Penicillin V 1.6 million units thrice-daily for 10 days
Study: 23594463
Drug: Amoxicillin 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin 1,000 mg thrice-daily for 10 days
Study: 17666194
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with telmisartan and ramipril (an ACE inhibitor)
Study: 11084548
Drug: High-dose intravaginal
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intravaginal misoprostol (600 microg vaginally)
Study: 9487348
Drug: Colistin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colistin (2 MU tds intravenously) with a second anti-pseudomonal antibiotic (dual therapy)
Study: 8368227
Drug: Pamidronate (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamidronate (all doses)
Study: 30693611
Drug: Project-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Project-based treatment (20 hours over 6 weeks)
Study: 28800382
Drug: Cotrimoxazole prophylaxis
Normalized name: Clotrimazole
DrugBank: Clotrimazole (DB00257)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cotrimoxazole prophylaxis (200 mg of SMX/40 mg of TMP once daily)
Study: 28800382
Drug: Regimens of
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimens of 30 mg kg-1 of SMX and 6 mg kg-1 of TMP for the 5-10 kg group and 25 mg kg-1 of SMX and 5 mg kg-1 of TMP for the 10-15 kg group
Study: 23969513
Drug: Pertuzumab, trastuzumab,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pertuzumab, trastuzumab, and docetaxel combination
Study: 15541448
Drug: bivalent HPV-16/18
Approvals — FDA: no, EMA: no, PMDA: no
Description: bivalent HPV-16/18 L1 virus-like particle vaccine
Study: 8034784
Drug: SofScale calculus
Normalized name: Anamirta cocculus fruit extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: SofScale calculus scaling gel
Study: 2659679
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of heat‐killed Leishmania mexicana amazonensis promastigotes and viable BCG
Study: 2659679
Drug: Meglumine antimoniate
Normalized name: meglumine antimoniate
DrugBank: Meglumine antimoniate (DB13732)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meglumine antimoniate chemotherapy
Study: 2659679
Drug: Combined immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined immunotherapy